ImmunoCellular shares plummet after PhII flop; Merck resumes supplying Zostavax to U.K.;

> The failure of ImmunoCellular's ($IMUC) brain cancer vaccine to meet a key Phase II endpoint caused the company's share price to halve in after-hours trading. Item

> Merck ($MRK) has resumed supplying shingles vaccine Zostavax to the U.K. after months of delays. Post

> Slow uptake is threatening to undermine the addition of flu vaccines to the U.K. childhood immunization schedule. News

> Ireland is continuing to pay the medical expenses of people who developed narcolepsy after receiving GlaxoSmithKline's ($GSK) swine flu vaccine. Article

> Ascend Biopharmaceuticals has partnered with 3M ($MMM) to develop a cancer vaccine. Piece

> A lack of knowledge about HPV vaccines is limiting uptake among racial minorities. Release

> Indian politicians continue to call for a ban on the pentavalent vaccine. Item

> The U.S. sustained its elimination of endemic measles and rubella through to 2011. Study

> A Pakistani scholar known as the "Father of the Taliban" has backed use of polio vaccines. Report

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.